The European Reference Network: the keystone for the management of rare thoracic cancers
Rocco Morra(Federico II University Hospital), Mario Giuliano(Regione Campania), Pietro De Placido(University of Naples Federico II), Liliana Montella(Ospedale Santa Maria), Marianna Tortora(Regione Campania), Vitoantonio Del Deo(University of Naples Federico II), Antonio D’Ambrosio(University of Naples Federico II), Sabino De Placido, Erica Pietroluongo(University of Naples Federico II), Giovannella Palmieri(Regione Campania)
Cited by 2
Related Papers
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|724
A Renewable Tissue Resource of Phenotypically Stable, Biologically and Ethnically Diverse, Patient-Derived Human Breast Cancer Xenograft Models
|Cancer Research|2013|485
Taxane-Based Combinations As Adjuvant Chemotherapy of Early Breast Cancer: A Meta-Analysis of Randomized Trials
|Journal of Clinical Oncology|2007|413
Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype
|Cancer Treatment Reviews|2018|282
Metastasis Dormancy in Estrogen Receptor–Positive Breast Cancer
|Clinical Cancer Research|2013|273